The Europe Cancer Gene Therapy Market would witness market growth of 20.3% CAGR during the forecast period (2022-2028).
Favorable government therapeutic laws would further enhance numerous prospects, resulting in the expansion of the cancer gene therapy market over the projection period. However, high treatment costs and undesired immune reactions are projected to limit the growth of the cancer gene therapy market. In addition, compared to prior years, there was an increase in novel gene therapy pipeline developments in 2020. As a result, the number of clinical trials, product launches, collaborations, and product innovations are increasing.
Over the last few years, the gene therapy market has seen a series of changes. Initially, gene therapy for monogenetic illnesses was popular; however, the market for gene therapy for cancer treatment is growing in popularity. Cancer gene therapy is a method of treating cancer patients by putting therapeutic DNA into their bodies.
The German cancer gene has a lot of room for growth in the coming years. One of the primary reasons driving country growth is a better regulatory environment. Over the last few years, German regulatory authorities have simplified the regulatory process, making it easier for industry participants to advertise their medicines in Germany. Furthermore, a growing interest among healthcare experts in the availability of advanced cancer gene therapy would help the country prosper.
Lung cancer is caused by the uncontrollable proliferation of aberrant cells in one or both lungs. Persons who smoke have the highest risk of lung cancer, despite the fact that it can affect people who have never smoked. The time and number of cigarettes smoked by a patient increase the risk of lung cancer. Other risk factors include secondhand smoke, asbestos, certain metals, some organic compounds, radiation, air pollution, and diesel exhaust at the workplace or in the environment.
The Germany market dominated the Europe Cancer Gene Therapy Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $324.3 million by 2028. The UK market is poised to grow at a CAGR of 19.3% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 21.2% during (2022 - 2028).
Based on Therapy, the market is segmented into Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer. Based on End User, the market is segmented into Hospitals, Diagnostic centers and Research Institutes. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Cancer Gene Therapy Market Size will Hit $5 Billion by 2028, at a CAGR of 21.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, GlaxoSmithKline PLC (GSK), Amgen, Inc., Bristol Myers, Squibb Company, Karyopharm Therapeutics, Inc., Gilead Sciences, Inc., Adaptimmune Limited, Genelux Corporation, and Sarepta Therapeutics, Inc
By Therapy
By End User
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 